Full Text Journal Articles by
Author Christopher G Wood

Advertisement

Find full text journal articles






Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival.

Alberto C Pieretti, Daniel D Shapiro, Mary E Westerman, Hyunsoo Hwang, Xuemei Wang, Luis A Segarra, Matthew T Campbell, Nizar M Tannir, Eric Jonasch, Surena F Matin, Christopher G Wood, Jose A Karam,

<h4>Objective</h4>Tumor shrinkage of at least 10% after presurgical targeted molecular therapy (TMT) in renal cell carcinoma (RCC) patients has been associated with better overall survival (OS) outcomes. We characterized primary and metastatic tumor diameter response and OS in patients with metastatic clear cell RCC (ccRCC) who received preoperative TMT, immunotherapy, ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.

Jose A Karam, Maneka Puligandla, Keith T Flaherty, Robert G Uzzo, Surena F Matin, Michael R Pins, Christopher G Wood, Christopher Kane, Michael A S Jewett, Se Eun Kim, Janice P Dutcher, Robert S DiPaola, Naomi B Haas,

<h4>Objectives</h4>To study the effects of adjuvant therapy in patients with sarcomatoid renal cell carcinoma (sRCC) enrolled in the randomised phase III clinical trial E2805.<h4>Patients and methods</h4>The original trial (E2805) was a randomised, double-blinded phase III clinical trial comparing outcomes in 1943 patients with RCC accrued between 2006 and 2010 and ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity.

Shi-Ming Tu, Miao Zhang, Christopher G Wood, Louis L Pisters,

In many respects, heterogeneity is one of the most striking revelations and common manifestations of a stem cell origin of cancer. We observe heterogeneity in myriad mixed tumors including testicular, lung, and breast cancers. We recognize heterogeneity in diverse tumor subtypes in prostate and kidney cancers. From this perspective, we ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(16):]

Cited: 0 times

View full text PDF listing >>



Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma.

Alberto C Pieretti, Mary E Westerman, Alexandria Childs, Niki Millward, Daniel D Shapiro, Kanishka Sircar, Priya Rao, Eric Jonasch, Matthew T Campbell, Nizar M Tannir, Surena F Matin, Christopher G Wood, Jose A Karam,

<h4>Purpose</h4>The presence of sarcomatoid features and/or lymph node-positive disease may be associated with a worse prognosis in chromophobe renal cell carcinoma (ChRCC). We sought to better characterize patients' long-term outcomes with these features compared with those without these features.<h4>Materials and methods</h4>We identified 300 patients treated for sporadic, unilateral, nonmetastatic ChRCC ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.

Brian De, Aradhana M Venkatesan, Pavlos Msaouel, Amol J Ghia, Jing Li, Debra N Yeboa, Quynh-Nhu Nguyen, Andrew J Bishop, Eric Jonasch, Amishi Y Shah, Matthew T Campbell, Jennifer Wang, Amado J Zurita-Saavedra, Jose A Karam, Christopher G Wood, Surena F Matin, Nizar M Tannir, Chad Tang,

<h4>Objective</h4>To study whether delivering definitive radiotherapy (RT) to sites of oligoprogression in metastatic renal cell carcinoma (mRCC) enabled deferral of systemic therapy (ST) changes without compromising disease control or survival.<h4>Patients and methods</h4>We identified patients with mRCC who received RT to three or fewer sites of extracranial progressive disease between 2014 ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Sophie J Cowman, Daniel G Fuja, Xian-De Liu, Rebecca S Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M Agarwal, Lyska L Emerson, Sheryl R Tripp, Jeffrey S Mohlman, Miekan Stonhill, Guillermina Garcia, Christopher J Conley, Adam A Olalde, Timothy Sargis, Adela Ramirez-Torres, Jose A Karam, Christopher G Wood, Kanishka Sircar, Pheroze Tamboli, Kenneth Boucher, Benjamin Maughan, Benjamin T Spike, Thai H Ho, Neeraj Agarwal, Eric Jonasch, Mei Yee Koh,

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(11):3265]

Cited: 0 times

View full text PDF listing >>



Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy.

Andrew G McIntosh, Eric C Umbreit, Christopher G Wood, Surena F Matin, Jose A Karam,

Unlike urothelial carcinoma of the bladder, there is no guideline-based consensus on whether a lymph node dissection (LND) should be performed at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). Variable lymphatic drainage based on primary tumor location, lack of prospective trials, and difficulties in developing ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2021, 10(5):2233-2245]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.

Andrew J Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K Bathala, Amishi Y Shah, Eric Jonasch, Vince D Cataldo, Giannicola Genovese, Jose A Karam, Christopher G Wood, Nizar M Tannir, Pavlos Msaouel,

<h4>Purpose</h4>To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC.<h4>Methods</h4>We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution.<h4>Results</h4>Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(9):]

Cited: 0 times

View full text PDF listing >>



Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies.

Mohamed E Abdelsalam, Sharjeel H Sabir, Samuel B Kusin Ba, Jose A Karam, Surena F Matin, Christopher G Wood, Kamran Ahrar,

<b>OBJECTIVE.</b> The purpose of this article is to investigate the oncologic effectiveness and survival outcomes of percutaneous image-guided thermal ablation for clinical T1a renal cell carcinoma (RCC) in patients with other primary nonrenal malignancies. <b>MATERIALS AND METHODS.</b> We reviewed records of patients with histologically proven T1a RCC (< 4.0 cm) ... Read more >>

AJR Am J Roentgenol (AJR. American journal of roentgenology)
[2021, 217(1):157-163]

Cited: 0 times

View full text PDF listing >>



Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.

Andres F Correa, Opeyemi A Jegede, Naomi B Haas, Keith T Flaherty, Michael R Pins, Adebowale Adeniran, Edward M Messing, Judith Manola, Christopher G Wood, Christopher J Kane, Michael A S Jewett, Janice P Dutcher, Robert S DiPaola, Michael A Carducci, Robert G Uzzo,

<h4>Background</h4>Risk stratification for localized renal cell carcinoma (RCC) relies heavily on retrospective models, limiting their generalizability to contemporary cohorts.<h4>Objective</h4>To introduce a contemporary RCC prognostic model, developed using prospective, highly annotated data from a phase III adjuvant trial.<h4>Design, setting, and participants</h4>The model utilizes outcome data from the ECOG-ACRIN 2805 (ASSURE) RCC ... Read more >>

Eur Urol (European urology)
[2021, 80(1):20-31]

Cited: 0 times

View full text PDF listing >>



Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Leah K Shaw, Andrew J Wiele, Kanishka Sircar, Christopher G Wood, Pavlos Msaouel,

Targeting the programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) pathways using the combination immune checkpoint inhibitors (ICI) nivolumab and ipilimumab is an approved frontline therapy for patients with metastatic clear-cell renal cell carcinoma (mccRCC). Certain populations pose clinical challenges due to exclusion from large clinical trials ... Read more >>

Cancer Treat Res Commun (Cancer treatment and research communications)
[2021, 27:100349]

Cited: 0 times

View full text PDF listing >>



Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.

Toni K Choueiri, Michael B Atkins, Ziad Bakouny, Maria I Carlo, Charles G Drake, Eric Jonasch, Payal Kapur, Bryan Lewis, W Marston Linehan, Michael J Mitchell, Sumanta K Pal, Kevin Pels, Susan Poteat, W Kimryn Rathmell, Brian I Rini, Sabina Signoretti, Nizar Tannir, Robert Uzzo, Christopher G Wood, Hans J Hammers,

Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, 113(3):234-243]

Cited: 1 time

View full text PDF listing >>



The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma.

Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Jose A Karam, Christopher G Wood,

The management of metastatic renal cell carcinoma (mRCC) continues to be a therapeutic challenge; however, the options for systemic therapy in this setting have exploded over the past 20 years. From the advent of toxic cytokine therapy to the subsequent discovery of targeted therapy (TT) and immune checkpoint inhibitors, the ... Read more >>

Indian J Urol (Indian journal of urology : IJU : journal of the Urological Society of India)
[2021, 37(1):13-19]

Cited: 0 times

View full text PDF listing >>



Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.

Eric C Umbreit, Bilal A Siddiqui, Michael J Hwang, Aron Y Joon, Tapati Maity, Mary E Westerman, Kelly W Merriman, Hussam Alhasson, Joma Uthup, Tao Guo, Joseph A Moore, John F Ward, Jose A Karam, Christopher G Wood, Louis L Pisters, Miao Zhang, Shi-Ming Tu,

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This is particularly relevant in a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns tumor heterogeneity and cancer dormancy in subsequent second malignancies (subsequent malignant neoplasms (SMNs)). From our tumor ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(12):]

Cited: 3 times

View full text PDF listing >>



Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.

Brian Rini, E Jason Abel, Laurence Albiges, Axel Bex, James Brugarolas, Ronald M Bukowski, Jonathan A Coleman, Charles G Drake, Robert A Figlin, Andy Futreal, Hans Hammers, Thomas Powles, W Kimryn Rathmell, Christopher J Ricketts, Samra Turajlic, Christopher G Wood, Bradley C Leibovich,

Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, 19(2):167-175]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.

Christopher G Wood, James E Ferguson, Joel S Parker, Dominic T Moore, Jennifer G Whisenant, Susan J Maygarden, Eric M Wallen, William Y Kim, Mathew I Milowsky, Kathryn E Beckermann, Nancy B Davis, Scott M Haake, Jose A Karam, Dante S Bortone, Benjamin G Vincent, Thomas Powles, W Kimryn Rathmell,

BACKGROUNDSurgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%-40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on the tumor genetic heterogeneity or the immune milieu is ... Read more >>

JCI Insight (JCI insight)
[2020, 5(22):]

Cited: 2 times

View full text PDF listing >>



Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.

Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, Barrett Z McCormick, Tharakeswara K Bathala, Jianjun Gao, Robert Horn, Lianchun Xiao, Kanishka Sircar, Matthew T Campbell, Amishi Y Shah, Sangeeta Goswami, Amado J Zurita, Eric Jonasch, Surena F Matin, Christopher G Wood, Jose A Karam, Padmanee Sharma, Nizar M Tannir,

<h4>Introduction</h4>Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-cell (sccRCC) to non-clear cell epithelial histology (snccRCC).<h4>Methods</h4>We performed retrospective analysis of sRCC patients who received ICI at ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(2):134.e9-134.e16]

Cited: 0 times

View full text PDF listing >>



Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications.

Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Luis A Segarra, Levi C Holland, Bryan M Fellman, Stephen B Williams, Arun Z Thomas, Shi-Ming Tu, Curtis A Pettaway, Louis L Pisters, John F Ward, Christopher G Wood, Jose A Karam,

<h4>Background</h4>Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) is an essential, yet potentially morbid, therapy for the management of patients with advanced germ cell tumors. In the current study, the authors sought to define the complication profile of PC-RPLND using validated grading systems for intraoperative adverse events (iAEs) and early postoperative complications.<h4>Methods</h4>Between 2000 and ... Read more >>

Cancer (Cancer)
[2020, 126(22):4878-4885]

Cited: 1 time

View full text PDF listing >>



Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question?

Daniel D Shapiro, Mary E Westerman, Jose A Karam, Christopher G Wood,

Determining the appropriate patients for cytoreductive nephrectomy (CN) has evolved with the integration of more effective systemic therapies for patients with metastatic renal cell carcinoma (mRCC). While previously considered to be first-line therapy for mRCC, CN has not demonstrated a significant survival advantage over systemic therapy in more recent randomized ... Read more >>

Cancer J (Cancer journal (Sudbury, Mass.))
[2020, 26(5):382-389]

Cited: 0 times

View full text PDF listing >>



Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.

Mary E Westerman, Daniel D Shapiro, Nizar M Tannir, Matthew T Campbell, Surena F Matin, Jose A Karam, Christopher G Wood,

<h4>Objective</h4>To validate models currently used to predict metastatic renal cell carcinoma (mRCC) outcomes in a cohort of patients undergoing cytoreductive nephrectomy (CN).<h4>Patients and methods</h4>A total of 10 RCC prognostic models (International Metastatic RCC Database Consortium [IMDC]; Memorial Sloan Kettering Cancer Center [MSKCC]; Culp; Leibovich; University of California at Los Angeles ... Read more >>

BJU Int (BJU international)
[2020, 126(6):745-753]

Cited: 1 time

View full text PDF listing >>



Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Mary E Westerman, Christopher G Wood,

Ann Transl Med (Annals of translational medicine)
[2020, 8(16):1037]

Cited: 0 times

View full text PDF listing >>



Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Sophie J Cowman, Daniel G Fuja, Xian-De Liu, Rebecca S Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M Agarwal, Lyska L Emerson, Sheryl R Tripp, Jeffrey S Mohlman, Miekan Stonhill, Guillermina Garcia, Christopher J Conley, Adam A Olalde, Timothy Sargis, Adela Ramirez-Torres, Jose A Karam, Christopher G Wood, Kanishka Sircar, Pheroze Tamboli, Kenneth Boucher, Benjamin Maughan, Benjamin T Spike, Thai H Ho, Neeraj Agarwal, Eric Jonasch, Mei Yee Koh,

<h4>Purpose</h4>Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel-Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(18):4970-4982]

Cited: 3 times

View full text PDF listing >>



Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.

Mary E Westerman, Daniel D Shapiro, Christopher G Wood, Jose A Karam,

There has been strong interest in using neoadjuvant therapy to decrease recurrence rates and facilitate surgical resection in locally advanced renal cell carcinoma. To date, no evidence exists to support improvement in oncologic outcomes with neoadjuvant therapy. Likewise, although targeted therapies have shown efficacy in tumor downsizing, this does not ... Read more >>

Urol Clin North Am (The Urologic clinics of North America)
[2020, 47(3):329-343]

Cited: 0 times

View full text PDF listing >>



Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Andrew G McIntosh, Eric C Umbreit, Levi C Holland, Cindy Gu, Nizar M Tannir, Surena F Matin, Jose A Karam, Stephen H Culp, Christopher G Wood,

<h4>Background</h4>The management of metastatic renal cell carcinoma (mRCC) has evolved rapidly, and results from the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial bring into question the utility of cytoreductive nephrectomy (CN). The objective of this study was to examine overall survival (OS) and identify risk factors associated with ... Read more >>

Cancer (Cancer)
[2020, 126(17):3950-3960]

Cited: 2 times

View full text PDF listing >>



EDITORIAL COMMENT.

Daniel D Shapiro, Jose A Karam, Christopher G Wood,

Urology (Urology)
[2020, 136:175]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.2273 s